Metabolomics

Dataset Information

0

Mass Spectrometry-Based Metabolic Fingerprinting Contributes to Unveil the Role of RSUME in Renal Cell Carcinoma Cell Metabolism


ABSTRACT: Clear cell renal cell carcinoma (ccRCC) is a heterogeneous disease with 50-80% patients exhibiting mutations in the von Hippel-Lindau (VHL) gene. RSUME (RWD domain (termed after three major RWD-containing proteins: RING finger-containing proteins, WD-repeat-containing proteins, and yeast DEAD (DEXD)-like helicases)-containing protein small ubiquitin-related modifier (SUMO) enhancer) acts as a negative regulator of VHL function in normoxia. A discovery-based metabolomics approach was developed by means of ultraperformance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (MS) for fingerprinting the endometabolome of a human ccRCC cell line 786-O and three other transformed cell systems (n = 102) with different expressions of RSUME and VHL. Cross-validated orthogonal projection to latent structures discriminant analysis models were built on positive, negative, and a combination of positive- and negative-ion mode MS data sets. Discriminant feature panels selected by an iterative multivariate classification allowed differentiating cells with different expressions of RSUME and VHL. Fifteen identified discriminant metabolites with level 1, including glutathione, butyrylcarnitine, and acetylcarnitine, contributed to understand the role of RSUME in ccRCC. Altered pathways associated with the RSUME expression were validated by biological and bioinformatics analyses. Combined results showed that in the absence of VHL, RSUME is involved in the downregulation of the antioxidant defense system, whereas in the presence of VHL, it acts in rerouting energy-related pathways, negatively modulating the lipid utilization, and positively modulating the fatty acid synthesis, which may promote deposition in droplets.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse phase, Liquid Chromatography MS - positive - reverse phase

SUBMITTER: Manuela Romina Martinefski 

PROVIDER: MTBLS1935 | MetaboLights | 2021-10-06

REPOSITORIES: MetaboLights

Dataset's files

Source:
Action DRS
MTBLS1935 Other
FILES Other
a_MTBLS1935_LC-MS_negative_reverse-phase_metabolite_profiling.txt Txt
a_MTBLS1935_LC-MS_positive_reverse-phase_metabolite_profiling.txt Txt
files-all.json Other
Items per page:
1 - 5 of 9
altmetric image

Publications

Mass Spectrometry-Based Metabolic Fingerprinting Contributes to Unveil the Role of RSUME in Renal Cell Carcinoma Cell Metabolism.

Martinefski Manuela R MR   Elguero Belén B   Knott María Elena ME   Gonilski David D   Tedesco Lucas L   Gurevich Messina Juan M JM   Pollak Cora C   Arzt Eduardo E   Monge María Eugenia ME  

Journal of proteome research 20201030 1


Clear cell renal cell carcinoma (ccRCC) is a heterogeneous disease with 50-80% patients exhibiting mutations in the von Hippel-Lindau (VHL) gene. RSUME (RWD domain (termed after three major RWD-containing proteins: RING finger-containing proteins, WD-repeat-containing proteins, and yeast DEAD (DEXD)-like helicases)-containing protein small ubiquitin-related modifier (SUMO) enhancer) acts as a negative regulator of VHL function in normoxia. A discovery-based metabolomics approach was developed by  ...[more]

Similar Datasets

2018-11-14 | MTBLS737 | MetaboLights
2023-05-10 | PXD036428 | Pride
2014-12-23 | GSE50053 | GEO
2024-09-10 | GSE276431 | GEO
2020-11-20 | MTBLS1839 | MetaboLights
2014-12-23 | E-GEOD-50053 | biostudies-arrayexpress
2024-03-15 | MTBLS8901 | MetaboLights
2017-12-12 | GSE107848 | GEO
2019-04-03 | GSE129255 | GEO
2020-07-22 | E-MTAB-9380 | biostudies-arrayexpress